Florida State University, 2313 University Center, Bldg. C, Tallahassee, FL 32306.
J Manag Care Spec Pharm. 2014 Dec;20(12):1162-82. doi: 10.18553/jmcp.2014.20.12.1162.
Medication therapy management (MTM) is one form of a medication benefit program offered by public and private health providers and insurers. Although the term was first coined in 2003, MTM in its earlier forms has been used since the 1990s as a mechanism to improve health metrics for medically complex patients. Its role expanded with the passage of Medicare Part D, as a mandated component to help patients with multiple chronic conditions, high drug costs, and high utilization to improve the effectiveness and safety of their medication treatments.
To review the evidence on MTM effectiveness in order to (a) provide information on its establishment and goals and (b) summarize research findings under 3 outcomes: economic, clinical, and humanistic.
PubMed, a search engine service of the National Center for Biotechnology Information was utilized by trained research assistants to search for articles with the following key words: MTM, randomized controlled trials on MTM, evaluation of MTM, comprehensive medication review, medication action plan, special needs population, special needs plans, Medicaid, disease management, adherence, non-adherence, compliance, chronic conditions, disabling chronic conditions, and disability. Additional searches were conducted for key articles in references listed in the most recent review articles. The initial search identified nearly 300 articles.
When evaluated, most studies found economic benefits, but the quality of research design and end point measures varied considerably across evaluations. Clinical outcomes encompassed a wide range of potential metrics, from service utilization, to individual patient and population outcomes, and quality of care. Quality measures such as provider-prescribing habits and medication adherence were frequently found to improve. As noted with the economic outcomes studies, overall rigor of study design was suboptimal, and often underpowered. Few studies have focused on humanistic outcomes such as improved patient quality of life.
Evidence suggests that MTM services are a promising way to manage complex patients, but there are gaps in the literature largely because of the limited number of studies with strong designs. Stronger evaluation of MTM programs is warranted.
药物治疗管理(MTM)是公共和私人医疗服务提供者和保险公司提供的一种药物福利计划形式。尽管该术语于 2003 年首次提出,但早在 20 世纪 90 年代,MTM 作为一种改善患有复杂疾病的患者健康指标的机制就已经在使用了。随着医疗保险部分 D 的通过,其作用得到了扩大,作为一种强制性的组成部分,旨在帮助患有多种慢性疾病、药物费用高和利用率高的患者,以提高他们药物治疗的有效性和安全性。
审查 MTM 有效性的证据,以便 (a) 提供其建立和目标的信息,(b) 总结以下 3 个结果的研究结果:经济、临床和人文。
受过培训的研究助理利用美国国家生物技术信息中心的搜索引擎服务 PubMed 搜索以下关键词的文章:MTM、MTM 的随机对照试验、MTM 的评估、综合药物审查、药物行动计划、特殊需求人群、特殊需求计划、医疗补助、疾病管理、依从性、不依从性、合规性、慢性疾病、致残性慢性疾病和残疾。还对最近的综述文章中列出的参考文献中的关键文章进行了额外搜索。最初的搜索确定了近 300 篇文章。
当进行评估时,大多数研究发现了经济上的好处,但研究设计和终点测量的质量在评估中差异很大。临床结果涵盖了广泛的潜在指标,从服务利用到个体患者和人群结果以及护理质量。经常发现质量指标(如提供者的处方习惯和药物依从性)得到改善。与经济结果研究一样,研究设计的总体严谨性较差,而且往往力不从心。很少有研究关注改善患者生活质量等人文结果。
证据表明,MTM 服务是管理复杂患者的一种有前途的方法,但文献中存在空白,主要是因为具有强大设计的研究数量有限。有必要对 MTM 计划进行更有力的评估。